The Diabetic Gastroparesis drugs in development market research report provides comprehensive information on the therapeutics under development for Diabetic Gastroparesis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Diabetic Gastroparesis. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Diabetic Gastroparesis and features dormant and discontinued products.

GlobalData tracks seven drugs in development for Diabetic Gastroparesis by seven companies/universities/institutes. The top development phase for Diabetic Gastroparesis is phase ii with five drugs in that stage. The Diabetic Gastroparesis pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Diabetic Gastroparesis pipeline products market are: Processa Pharmaceuticals, Johnson & Johnson and PTC Therapeutics.

The key targets in the Diabetic Gastroparesis pipeline products market include 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4), D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2), and D3 Dopamine Receptor (Dopamine D3 Receptor or DRD3).

The key mechanisms of action in the Diabetic Gastroparesis pipeline product include 5-Hydroxytryptamine Receptor 4 (5 HT4 or Serotonin Receptor 4 or HTR4) Agonist with three drugs in Phase III. The Diabetic Gastroparesis pipeline products include one routes of administration with the top ROA being Oral and two key molecule types in the Diabetic Gastroparesis pipeline products market including Small Molecule, and Cell Therapy.

Diabetic Gastroparesis overview

Gastroparesis is a long-term complication of diabetes that involves the stomach and affects digestion. Prolonged high blood sugar levels can damage nerves in many parts of the body, including the vagus nerve, which controls contractions of the stomach during digestion. Spasms, abdominal pain, feelings of fullness after a small amount of food, and other symptoms such as nausea and vomiting, reflux, heartburn, and bloating are often experienced with gastroparesis. Loss of appetite and reduced absorption of nutrients may also be experienced. Gastroparesis can lead to weight loss and malnutrition.

For a complete picture of Diabetic Gastroparesis’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.